Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders

Alzheimer disease (AD) is a neurodegenerative disorder lacking an effective therapy. The etiology is controversial and among different drug strategies, the cholinergic approach has gained great interest owing to biochemical and pharmacological evidence of the crucial role of acetylcholine in cogniti...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of drug metabolism and pharmacokinetics Vol. 19; no. 3; p. 179
Main Authors Cereda, E, Brambilla, A, Ezhaya, A, Gaida, W, Mendla, K, Monferini, E, Pitsikas, N, Schiavi, G B, Sagrada, A
Format Journal Article
LanguageEnglish
Published France 01.07.1994
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Alzheimer disease (AD) is a neurodegenerative disorder lacking an effective therapy. The etiology is controversial and among different drug strategies, the cholinergic approach has gained great interest owing to biochemical and pharmacological evidence of the crucial role of acetylcholine in cognitive functions. Several attempts exploiting the boosting of the cholinergic system are currently under way. Inhibitors of the acetylcholinesterase enzyme sustain the availability of the natural transmitter by limiting its removal from the synapse. In a different approach, exogenous agonists may substitute acetylcholine itself. In this way the issue of the extensive cholinergic cell loss occurring in AD and leading to a reduction of cholinergic functions, could be advantageously bypassed. Moreover the discovery of different muscarinic receptor subtypes, most notably the M1 subtype as that involved in the postsynaptic transmission, has offered new opportunities to face the problem in a very specific way. In this line of research, we have now identified BIMC 182 as a new functionally selective M1 agonist. Whereas its affinity for the different receptor subtypes is almost similar (radioreceptor binding), its functional selectivity is pointed out by specific "in vitro" models. BIMC 182 behaves as a full agonist at M1 (rat superior cervical ganglion, pD2 4.8) and as a partial agonist at M2 and M3 sites (g.p. heart pD2 = 5.4 and g.p. ileum pD2 = 4.5). The agonist profile is further confirmed in hm1 transfected CHO cells where the compound stimulates PI turnover. BIMC 182 penetrates well the brain as shown by the increase in the energy of the low frequency band (theta waves) in the cortical EEG of rabbits (3 mg/kg i.v.).
AbstractList Alzheimer disease (AD) is a neurodegenerative disorder lacking an effective therapy. The etiology is controversial and among different drug strategies, the cholinergic approach has gained great interest owing to biochemical and pharmacological evidence of the crucial role of acetylcholine in cognitive functions. Several attempts exploiting the boosting of the cholinergic system are currently under way. Inhibitors of the acetylcholinesterase enzyme sustain the availability of the natural transmitter by limiting its removal from the synapse. In a different approach, exogenous agonists may substitute acetylcholine itself. In this way the issue of the extensive cholinergic cell loss occurring in AD and leading to a reduction of cholinergic functions, could be advantageously bypassed. Moreover the discovery of different muscarinic receptor subtypes, most notably the M1 subtype as that involved in the postsynaptic transmission, has offered new opportunities to face the problem in a very specific way. In this line of research, we have now identified BIMC 182 as a new functionally selective M1 agonist. Whereas its affinity for the different receptor subtypes is almost similar (radioreceptor binding), its functional selectivity is pointed out by specific "in vitro" models. BIMC 182 behaves as a full agonist at M1 (rat superior cervical ganglion, pD2 4.8) and as a partial agonist at M2 and M3 sites (g.p. heart pD2 = 5.4 and g.p. ileum pD2 = 4.5). The agonist profile is further confirmed in hm1 transfected CHO cells where the compound stimulates PI turnover. BIMC 182 penetrates well the brain as shown by the increase in the energy of the low frequency band (theta waves) in the cortical EEG of rabbits (3 mg/kg i.v.).
Author Cereda, E
Ezhaya, A
Monferini, E
Mendla, K
Brambilla, A
Schiavi, G B
Sagrada, A
Gaida, W
Pitsikas, N
Author_xml – sequence: 1
  givenname: E
  surname: Cereda
  fullname: Cereda, E
  organization: Boehringer Ingelheim Italia, Milan
– sequence: 2
  givenname: A
  surname: Brambilla
  fullname: Brambilla, A
– sequence: 3
  givenname: A
  surname: Ezhaya
  fullname: Ezhaya, A
– sequence: 4
  givenname: W
  surname: Gaida
  fullname: Gaida, W
– sequence: 5
  givenname: K
  surname: Mendla
  fullname: Mendla, K
– sequence: 6
  givenname: E
  surname: Monferini
  fullname: Monferini, E
– sequence: 7
  givenname: N
  surname: Pitsikas
  fullname: Pitsikas, N
– sequence: 8
  givenname: G B
  surname: Schiavi
  fullname: Schiavi, G B
– sequence: 9
  givenname: A
  surname: Sagrada
  fullname: Sagrada, A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/7867659$$D View this record in MEDLINE/PubMed
BookMark eNotT01LAzEUzKFSa-3Fu5A_sJpsstnkqMVWoSKInsvb5D0b6e6WZHvov7eLnct8MAzMDZt0fYeM3UnxIIWoH59XQklrnXQTNhOqtkXtjLlmi5x_xRnKuqoyUzatralN5Wbs8x1D9LGDPfc7bGMe0on3xNtj9pBiFz2Hn74755lTn_iwQz4khKHFbhiLAUcVgYeY-xQw5Vt2RbDPuLjwnH2vXr6Wr8XmY_22fNoUXkk5FNo40lqFRoEGsgFcqMhrjyBsQ6asdEkSyI9GkXJYESBR8IFcaEpVztn9_-7h2LQYtocUW0in7eVb-QdrkVOH
CitedBy_id crossref_primary_10_1177_108705719700200205
crossref_primary_10_1016_j_ddstr_2006_10_014
crossref_primary_10_1038_sj_bjp_0701844
crossref_primary_10_1016_S0306_4522_98_00626_5
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1007/BF03188919
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 7867659
Genre Journal Article
GroupedDBID ---
-EM
.GJ
06D
0R~
0VY
1N0
2.D
2JN
2KG
2VQ
30V
4.4
406
408
40D
53G
5GY
67N
96X
AAAUJ
AABHQ
AACDK
AAEOY
AAEWM
AAIAL
AAIKX
AAJKR
AANXM
AANZL
AAQLM
AARHV
AARTL
AASML
AATNV
AAWCG
AAYIU
AAYOK
AAYQN
AAYTO
AAYZH
AAZMS
ABAKF
ABDZT
ABFTV
ABHLI
ABJNI
ABJOX
ABKCH
ABKMS
ABPLI
ABQBU
ABTKH
ABTMW
ABWHX
ABXPI
ACAOD
ACBXY
ACCOQ
ACDTI
ACGFS
ACKNC
ACMLO
ACZOJ
ADFZG
ADHHG
ADHIR
ADINQ
ADKPE
ADRFC
ADURQ
ADYPR
ADZKW
AEBTG
AEFQL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETCA
AEVLU
AEXYK
AEYRQ
AFALF
AFBBN
AFLOW
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AJBLW
AJRNO
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
ANMIH
ASPBG
AVWKF
AWSVR
AXYYD
AZFZN
BBWZM
BGNMA
CGR
CSCUP
CUY
CVF
DNIVK
DPUIP
DU5
EBLON
EBS
ECM
EIF
EIOEI
EJD
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FLLZZ
FNLPD
FRRFC
FSGXE
GGRSB
GJIRD
GNWQR
GQ6
GQ7
H13
HF~
HMJXF
HRMNR
HVGLF
HZ~
ITM
IWAJR
J-C
JBSCW
JZLTJ
KOV
LLZTM
M4Y
NPM
NQJWS
NU0
O9-
P2P
R9I
RLLFE
ROL
RSV
S1Z
S27
S3A
S3B
SBL
SBY
SCLPG
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPKJE
SRMVM
SSLCW
T13
TSG
U2A
U9L
UG4
UTJUX
UZXMN
VC2
VDBLX
VFIZW
W48
WK8
Z45
Z7U
Z87
~A9
~JE
ID FETCH-LOGICAL-c311t-469f443db3a4af8da9d5fc4cea08bf62542f1afc8bf63f39e5faeffdcdf9db232
ISSN 0378-7966
IngestDate Wed Oct 16 01:00:06 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c311t-469f443db3a4af8da9d5fc4cea08bf62542f1afc8bf63f39e5faeffdcdf9db232
PMID 7867659
ParticipantIDs pubmed_primary_7867659
PublicationCentury 1900
PublicationDate 1994-07-01
PublicationDateYYYYMMDD 1994-07-01
PublicationDate_xml – month: 07
  year: 1994
  text: 1994-07-01
  day: 01
PublicationDecade 1990
PublicationPlace France
PublicationPlace_xml – name: France
PublicationTitle European journal of drug metabolism and pharmacokinetics
PublicationTitleAlternate Eur J Drug Metab Pharmacokinet
PublicationYear 1994
References 9729204 - Ann N Y Acad Sci. 1993 Dec 20;707:1-565
1448491 - Pharmacol Biochem Behav. 1992 Nov;43(3):949-51
7046051 - Science. 1982 Jul 30;217(4558):408-14
1404819 - JAMA. 1992 Nov 11;268(18):2523-9
2883303 - J Pharmacol Exp Ther. 1987 May;241(2):628-34
7470751 - Br J Pharmacol. 1980;71(2):362-4
3754610 - Life Sci. 1986 May 5;38(18):1653-62
3513886 - Br Med Bull. 1986 Jan;42(1):11-8
3395164 - Arch Int Pharmacodyn Ther. 1988 Mar-Apr;292:13-34
5535785 - Physiol Behav. 1970 Mar;5(3):335-9
1673209 - Lancet. 1991 Apr 27;337(8748):989-92
8441328 - Life Sci. 1993;52(5-6):473-80
References_xml
SSID ssj0000389556
Score 1.4434936
Snippet Alzheimer disease (AD) is a neurodegenerative disorder lacking an effective therapy. The etiology is controversial and among different drug strategies, the...
SourceID pubmed
SourceType Index Database
StartPage 179
SubjectTerms Alzheimer Disease - drug therapy
Animals
Brain - drug effects
CHO Cells
Cricetinae
Female
Learning - drug effects
Male
Muscarinic Agonists - metabolism
Muscarinic Agonists - pharmacology
Muscarinic Agonists - therapeutic use
Rabbits
Rats
Receptors, Muscarinic - metabolism
Title Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders
URI https://www.ncbi.nlm.nih.gov/pubmed/7867659
Volume 19
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9swFLbK0CQu08ao9gOQD4jLmqmpnR8-AoIhJFA1FdEbcmy_rgLairaHdv_8nmMnabqhAZcosR2rzffFeX72-x4hB8BNBGDagW6DCXgWxoHQggWgOmhAMxnrXEj78io-v-YX_ajfaPxejS6ZZd_V8p9xJa9BFcsQVxsl-wJky06xAM8RXzwiwnh8FsaXbmHcSnwUedvy9fL5VEm7MqO-ycHYSuNOy92E1cZybKhz3-BQ2mWaXINz-qSj3hut-nE-sFmnkTr3RXqNiVe_vkODdbayef7EpgGVtWiH40f5kNk8RzUv6unyl1zUi37Iobv1pnJLOH3hpHBL-HAsnJ4mwqVUKYdasUIptjJuhi6jzF_jebvcpR6mqQhrjRCLyUOObJLGSRz9v3JNWdvXbJANPLM5U72jJ_-IoyEXRW6l2_-Rurit_0Fb5K3vZm1ektsnvffknZ9Y0CPHkg-kYUbb5LDrsFm0aK8KtJu26CHtVprli4_kZ0klWlKJjoFWVKIFlShSiSKVaEkl27CgEi2ptEOuz057J-eBT7cRKBaGs4DHAjhnOmOSS0i1FDoCxZWR7TQDnCfzDoQSlL1gwAS-5NIAaKVB6Awt8yZ5MxqPzCdCU8mNEiZTRnPsQKURmvk66XDdMTFP2GfSdM_qduI0VW79Q_zyVMVXslWxbJdsAr7CZg_twVm2nyP3B9fyZas
link.rule.ids 786
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Medicinal+chemistry+of+muscarinic+agonists+for+the+treatment+of+dementia+disorders&rft.jtitle=European+journal+of+drug+metabolism+and+pharmacokinetics&rft.au=Cereda%2C+E&rft.au=Brambilla%2C+A&rft.au=Ezhaya%2C+A&rft.au=Gaida%2C+W&rft.date=1994-07-01&rft.issn=0378-7966&rft.volume=19&rft.issue=3&rft.spage=179&rft_id=info:doi/10.1007%2FBF03188919&rft_id=info%3Apmid%2F7867659&rft_id=info%3Apmid%2F7867659&rft.externalDocID=7867659
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-7966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-7966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-7966&client=summon